1. Home
  2. FNWD vs SPRO Comparison

FNWD vs SPRO Comparison

Compare FNWD & SPRO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Finward Bancorp

FNWD

Finward Bancorp

N/A

Current Price

$37.55

Market Cap

155.0M

Sector

Finance

ML Signal

N/A

Logo Spero Therapeutics Inc.

SPRO

Spero Therapeutics Inc.

HOLD

Current Price

$2.58

Market Cap

124.5M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
FNWD
SPRO
Founded
1994
2013
Country
United States
United States
Employees
N/A
N/A
Industry
Savings Institutions
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
155.0M
124.5M
IPO Year
1996
2017

Fundamental Metrics

Financial Performance
Metric
FNWD
SPRO
Price
$37.55
$2.58
Analyst Decision
Buy
Analyst Count
1
0
Target Price
$34.00
N/A
AVG Volume (30 Days)
4.5K
261.2K
Earning Date
04-28-2026
01-01-0001
Dividend Yield
1.29%
N/A
EPS Growth
44.90
N/A
EPS
1.42
N/A
Revenue
N/A
$47,977,000.00
Revenue This Year
$17.40
N/A
Revenue Next Year
$5.44
N/A
P/E Ratio
$26.23
N/A
Revenue Growth
N/A
N/A
52 Week Low
$26.46
$0.51
52 Week High
$39.99
$3.09

Technical Indicators

Market Signals
Indicator
FNWD
SPRO
Relative Strength Index (RSI) 53.96 67.53
Support Level $35.25 $2.15
Resistance Level $38.75 $2.70
Average True Range (ATR) 0.94 0.10
MACD 0.07 0.04
Stochastic Oscillator 79.50 85.85

Price Performance

Historical Comparison
FNWD
SPRO

About FNWD Finward Bancorp

Finward Bancorp is a bank holding company, which engages in the provision of financial services. It offers products and services related to Personal Banking, Cash Management, Saving Account, ebanking, Wealth Management, and Insurance Services. It is engaged in the business of attracting deposits from the general public and the origination of loans, mostly upon the security of single-family residences and commercial real estate, construction loans, commercial business loans, and municipal loans. Geographically, the activities are carried out through the United States.

About SPRO Spero Therapeutics Inc.

Spero Therapeutics Inc is a clinical-stage biopharmaceutical firm. It focuses on identifying, developing, and commercializing novel treatments for MDR (Multi-drug-resistant) bacterial infections and rare diseases. The company's product candidate, tebipenem pivoxil hydrobromide or tebipenem HBr, is designed to be an oral carbapenem-class antibiotic for use in adults to treat MDR Gram-negative infections. It is also developing SPR720, a novel oral antibiotic designed for the treatment of a rare, orphan disease caused by pulmonary non-tuberculous mycobacterial infections, or NTM disease. Besides, it is also focused on SPR206, a next-generation polymyxin investigational product candidate being developed as an IV-administered medicine to treat MDR Gram-negative infections in the hospital.

Share on Social Networks: